User Tools

Site Tools

Trace:
endocrine:glp1:dulaglutide

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
endocrine:glp1:dulaglutide [2026/02/13 00:18] – andrew2393cnsendocrine:glp1:dulaglutide [2026/02/13 00:19] (current) – andrew2393cns
Line 4: Line 4:
  
 Brand: Brand:
-* Trulicity+  * Trulicity
  
 → [[endocrine:glp1:start|GLP-1 Receptor Agonists Overview]] → [[endocrine:glp1:start|GLP-1 Receptor Agonists Overview]]
Line 14: Line 14:
 Effects: Effects:
  
-* Increases glucose-dependent insulin secretion +  * Increases glucose-dependent insulin secretion 
-* Decreases glucagon secretion +  * Decreases glucagon secretion 
-* Slows gastric emptying +  * Slows gastric emptying 
-* Increases satiety +  * Increases satiety 
-* Promotes weight loss+  * Promotes weight loss
  
 Net clinical effects: Net clinical effects:
  
-* Decreases HbA1c +  * Decreases HbA1c 
-* Reduces body weight +  * Reduces body weight 
-* Reduces major adverse cardiovascular events+  * Reduces major adverse cardiovascular events
  
 Low hypoglycemia risk unless combined with insulin or sulfonylureas. Low hypoglycemia risk unless combined with insulin or sulfonylureas.
Line 32: Line 32:
 ==== Type 2 Diabetes Mellitus ==== ==== Type 2 Diabetes Mellitus ====
  
-* Glycemic control +  * Glycemic control 
-* Cardiovascular risk reduction in high-risk patients+  * Cardiovascular risk reduction in high-risk patients
  
 ==== Atherosclerotic Cardiovascular Disease (ASCVD) ★ ==== ==== Atherosclerotic Cardiovascular Disease (ASCVD) ★ ====
Line 39: Line 39:
 Dulaglutide reduces: Dulaglutide reduces:
  
-* Myocardial infarction +  * Myocardial infarction 
-* Stroke +  * Stroke 
-* Cardiovascular death+  * Cardiovascular death
  
 Particularly beneficial in patients with established ASCVD or multiple risk factors. Particularly beneficial in patients with established ASCVD or multiple risk factors.
Line 51: Line 51:
 REWIND Trial: REWIND Trial:
  
-* Reduced major adverse cardiovascular events +  * Reduced major adverse cardiovascular events 
-* Included many patients without established ASCVD +  * Included many patients without established ASCVD 
-* Demonstrated strong primary prevention benefit+  * Demonstrated strong primary prevention benefit
  
 ===== Dosing ===== ===== Dosing =====
  
-* Once-weekly subcutaneous injection +  * Once-weekly subcutaneous injection 
-* No oral formulation +  * No oral formulation 
-* Gradual dose escalation improves tolerability+  * Gradual dose escalation improves tolerability
  
 ===== Adverse Effects ===== ===== Adverse Effects =====
Line 65: Line 65:
 Common: Common:
  
-* Nausea +  * Nausea 
-* Vomiting +  * Vomiting 
-* Diarrhea +  * Diarrhea 
-* Early satiety+  * Early satiety
  
 Serious (rare): Serious (rare):
  
-* Pancreatitis +  * Pancreatitis 
-* Gallbladder disease +  * Gallbladder disease 
-* Theoretical risk of medullary thyroid carcinoma+  * Theoretical risk of medullary thyroid carcinoma
  
 ===== Contraindications ===== ===== Contraindications =====
  
-* Personal or family history of medullary thyroid carcinoma +  * Personal or family history of medullary thyroid carcinoma 
-* MEN2 syndrome +  * MEN2 syndrome 
-* Severe gastrointestinal disease+  * Severe gastrointestinal disease
  
 Use caution in: Use caution in:
  
-* History of pancreatitis+  * History of pancreatitis
  
 ===== Dulaglutide vs Other GLP-1 Agents ===== ===== Dulaglutide vs Other GLP-1 Agents =====
Line 90: Line 90:
 [[endocrine:glp1:exenatide|Exenatide]] [[endocrine:glp1:exenatide|Exenatide]]
  
-* Shorter-acting formulations available+  * Shorter-acting formulations available
  
 [[endocrine:glp1:liraglutide|Liraglutide]] [[endocrine:glp1:liraglutide|Liraglutide]]
  
-* Daily injection +  * Daily injection 
-* Strong ASCVD data (LEADER trial)+  * Strong ASCVD data (LEADER trial)
  
 [[endocrine:glp1:semaglutide|Semaglutide]] [[endocrine:glp1:semaglutide|Semaglutide]]
  
-* Greater weight loss +  * Greater weight loss 
-* Oral option available+  * Oral option available
  
 Dulaglutide: Dulaglutide:
  
-* Weekly dosing +  * Weekly dosing 
-* Strong primary prevention data +  * Strong primary prevention data 
-* Well tolerated+  * Well tolerated
  
 ===== GLP-1 vs SGLT2 ===== ===== GLP-1 vs SGLT2 =====
Line 112: Line 112:
 Dulaglutide: Dulaglutide:
  
-* Strong ASCVD reduction +  * Strong ASCVD reduction 
-* Modest weight loss +  * Modest weight loss 
-* Minimal heart failure benefit+  * Minimal heart failure benefit
  
 [[endocrine:sglt2:start|SGLT2 Inhibitors]]: [[endocrine:sglt2:start|SGLT2 Inhibitors]]:
  
-* Strong heart failure benefit +  * Strong heart failure benefit 
-* Strong renal protection+  * Strong renal protection
  
 ===== Clinical Pearls ===== ===== Clinical Pearls =====
  
-* Weekly injection +  * Weekly injection 
-* Proven ASCVD benefit +  * Proven ASCVD benefit 
-* Good primary prevention data +  * Good primary prevention data 
-* Low hypoglycemia risk +  * Low hypoglycemia risk 
-* Not primary heart failure therapy+  * Not primary heart failure therapy
  
 ===== Related ===== ===== Related =====
  
-* [[endocrine:glp1:start|GLP-1 Receptor Agonists]] +  * [[endocrine:glp1:start|GLP-1 Receptor Agonists]] 
-* [[endocrine:sglt2:start|SGLT2 Inhibitors]] +  * [[endocrine:sglt2:start|SGLT2 Inhibitors]] 
-* [[cardio:intro:start|Cardiovascular Modules]]+  * [[cardio:intro:start|Cardiovascular Modules]]
endocrine/glp1/dulaglutide.txt · Last modified: by andrew2393cns